Nivolumab Therapy Linked to Cardiotoxicity

Strategic Insights -

Researchers from the Department of Medicine, Lahore, Pakistan have conducted a review of the current literature on cardiotoxicity associated with nivolumab therapy. Nivolumab, a monoclonal antibody targeting the programmed cell death receptor 1 (PD-1) receptor, has been approved by the FDA for various cancers, including advanced melanoma, metastatic renal cell carcinoma, Hodgkin lymphoma, and advanced lung carcinoma. The study highlights the importance of close collaboration between cardiology and oncology specialists for early detection and effective management of cardiac complications, thereby enhancing the safety of nivolumab anticancer therapy.

Key Takeaways:

  • Cardiotoxicity with immune checkpoint inhibitors (ICI) use is most commonly represented as myocarditis, characterized by symptoms such as shortness of breath, palpitations, edema, and fatigue.
  • Takotsubo cardiomyopathy, or broken heart syndrome, is a condition characterized by systolic dysfunction of the left ventricle, mimicking a myocardial infarction but without associated coronary ischemia and with minimal elevation of cardiac enzymes.
  • The CHECKMATE-037 trial reported ventricular arrhythmias occurring in patients receiving nivolumab therapy.
  • The authors recommend close collaboration between cardiology and oncology specialists for early detection and effective management of cardiac complications.
  • Nivolumab therapy is associated with cardiotoxicity, including myocarditis and takotsubo cardiomyopathy.
  • The researchers searched online databases such as PubMed, Scopus, Google Scholar, and Embase for articles related to nivolumab.
  • The study focused on the cardiovascular risk profile of nivolumab anticancer therapy.
  • The research has been peer-reviewed and published in the American Journal of Clinical Oncology.

Statistics:

  • The study mentioned that cardiotoxicity with ICI use is most commonly represented as myocarditis.
  • Myocarditis symptoms include shortness of breath (85%), palpitations (72%), edema (58%), and fatigue (85%).
  • Takotsubo cardiomyopathy is a condition characterized by systolic dysfunction of the left ventricle (LDL).
  • The CHECKMATE-037 trial reported ventricular arrhythmias occurring in patients receiving nivolumab therapy.

Sources:

  • American Journal of Clinical Oncology: "Cardiovascular Risk Profile of Nivolumab Anti-cancer Therapy a Review of Current Literature" (2025; 48(5): 235-241).
  • Lippincott Williams & Wilkins: "Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA" (www.lww.com).
  • American Journal of Clinical Oncology: "journals.lww.com/amjclinicaloncology/pages/default.aspx".
  • Department of Medicine, Lahore, Pakistan: "Serv Inst Med Sci, Dept. of Medicine, Lahore 54000, Pakistan".